News_News_Lynk Pharmaceutical (Hangzhou) Co., Ltd.

+86 0571-87711179

ychen1@lynkpharma.com

lynk Pharmaceutical (Hangzhou) Co., Ltd. | 浙ICP备18056091号-1 | Powered by www.300.cn | Manager

CONTACT US

website

ABOUT US

Company

Leadership

Scientific Advisory Board

291 Fucheng Road, Bldg 5-402, Jianggan, Hangzhou,
Zhejiang 310018, China

Home page

News

Lynk Pharmaceuticals Appoints Dr. Wang Weigand as Chief Medical Officer

Lynk Pharmaceuticals Appoints Dr. Wang Weigand as Chief Medical Officer

2021-01-20 15:21

Lynk Pharmaceuticals enters exclusive licensing agreements develop RAS inhibitors with a novel MOA

2020-07-28 11:51

HANGZHOU, China, July 27, 2020 /PRNewswire/ -- Lynk Pharmaceuticals is pleased to announce exclusive licensing agreements with Kobe
University and RIKEN Research Institute to develop RAS inhibitors with a novel MOA.

Lynk Pharmaceuticals successfully out-licensed a preclinical candidate

2020-07-19 16:59

Lynk Pharmaceuticals successfully out-licensed a preclinical candidate to a US company in April, 2020. Details will be announced at a later date.

On May 8, 2020, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, and Lynk Pharmaceuticals jointly founded IBMC-Lynk New Drug Discovery Center.

2020-07-19 16:57

On May 8, 2020, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences， and Lynk Pharmaceuticals jointly founded IBMC-Lynk
New Drug Discovery Center.

Lynk Pharmaceuticals' SPF Laboratory Animal Facility Passed Inspection

2019-12-12 17:28

Lynk Phamaceuticals' Laboratory Animal Facility has passed on-site inspection performed by the Office of Zhejiang Province Laboratory Animal
Management Committee and obtained the Laboratory Animal Use License in Dec. 6, 2019.

2019 New drug research and development symposium, Hilton, Guangzhou

2019-07-01 10:00

Dr. Zhao-Kui (ZK) Wan, founder & CEO, of Lynk Pharmaceuticals, was invited to present at the symposium